No significantly increased risks observed for autoimmune disorder, atopic or allergic disorder, neurodevelopmental disorder.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

The FDA has accepted the New Drug Application for doravirine/islatravir for adults with virologically-suppressed HIV-1 infection.